When I was a young child, we grew up on a wonderful five acres and we had a lot of different fruit trees and flower plants and I would go around and collect rose petals and different sticks and leaves and I would put them into boiling water and add perfumes and things and make my potions which I thought were going to cure cancer. So I was doing this back when I was five or six and I didn't know that years later I would be hopefully helping people for real.
Gilead — In the pursuit of science
I've always felt lucky that I've gotten to be able to do a job like this, where I get to think about a problem, come up with an idea, and then go into the lab and try it. It's not a cookie cutter process, there's no, standard operating procedure for discovery. It's still research; it may not work. Everybody's got to think and everybody's got to come up with new ideas. Because we're, we're trying to find something new.
Gilead develops therapies for HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases and cardiovascular conditions.
Your curiosity never disappears That's the key. So every time, every review, you find a new issue, new question, and you want to find a solution. You want to make your project move forward. So you never get tired.
You'll have these long stretches of trying to kind of chug through and push and keep moving, keep putting one foot in front of the other and then every once in a while, you'll get this fantastic email that has this beautiful data in it and it definitely gives you a jump start back into the lab. "Alright. This worked. Let's keep moving."
Discovery isn't made by any one person. It's often made when a group of individuals come together and start discussing data, and the ideas just begin flowing freely.
To solve these problems, you have to have experts in many different disciplines work productively, effectively together.
Everyone at some point finds a little piece of the puzzle that's really critically important. And it's all of those little things that add up together that make a compound that we're able to move forward.
When I'm working on something late at night and you'd rather go to sleep, but you think about why am I doing this? What is driving me to do this? And ultimately, it always comes back to the patient.
I think it's more being able to develop a product that will help a patient. That's my sole focus everyday.
We are trying to go after diseases that aren't being necessarily treated with what's available currently.
I work in the oncology area and that's an area that's personally touched my life, touched many peoples' lives in terms of losing someone close to you and that's an easy reminder to drive you.
There are a lot of people in the world that have all sorts of health problems and it's incredibly hard to sit by and watch and know that there's nothing that can be done and to know that you're able to put some hope into people's lives and give people a chance to live that otherwise they wouldn't have.
It's really fulfilling and gratifying to know what you're working on is so important and could be so useful. Not that many people get to do this sort of scientific discovery that could be so impactful.
It's an amazing feeling to know that something that you worked on that was just an idea is actually in the clinic currently and we're getting readouts from those clinical trials. And to know that you can be helping somebody right now, I mean, that's powerful and amazing.
Gilead plays a central role in developing single tablet regimens – with one pill once a day, patients can take all of their medication in each dose.
Our liver disease programs focus on expanding treatment options for chronic hepatitis B and C.
Our scientists are applying new knowledge about how cancers grow and spread to potentially enhance and improve cancer therapy.
Our medicines aim to help patients with cardiovascular disease return to their daily activities, and we are exploring potential new indications.
We research and develop treatments for serious respiratory conditions such as influenza, cystic fibrosis and other diseases of the lungs.
Gilead medicines treat severe fungal and parasitic infections, and address vision loss caused by degenerative eye diseases.
Gilead has made it a priority to help ensure worldwide access to its first-in-class treatment for hepatitis C. Learn more.
Access earnings press release, webcast link and slides for Gilead’s second quarter 2015 results. View materials.
September 17, 2015
through September 22, 2015
55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)